Viveve to Present at H.C. Wainwright 22nd Annual Global Investment Conference
ENGLEWOOD, CO / ACCESSWIRE / September 3, 2020 / Viveve Medical, Inc. (NASDAQ: VIVE) will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020, from 11:30 AM to 12:00 PM ET. Due to the pandemic, the event will be held virtually. Scott Durbin, CEO, will also engage in one-on-one meetings. The presentation will be available live on the company's website, with an archived version accessible for 30 days post-event. Viveve focuses on women's intimate health, with FDA clearance for its Viveve System and ongoing clinical development for SUI treatments.
- None.
- None.
ENGLEWOOD, CO / ACCESSWIRE / September 3, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer, will present at the H.C. Wainwright 22nd Annual Global Investment Conference. Mr. Durbin will also meet with members of the investment community during one-on-one meetings at the conference. Due to the coronavirus pandemic, all presentations and meetings will be virtual at the conference.
Event: H.C. Wainwright 22nd Annual Global Investment Conference
Date: Wednesday, September 16, 2020
Presentation Time: 11:30 AM - 12:00 PM ET
Location: Virtual Conference
The presentation will be webcast live on the Investors section of the Viveve website at ir.viveve.com. Interested parties can also access an archived version of the presentation on the Company's website for approximately 30 days after the event concludes.
About Viveve
Viveve Medical, Inc. is a medical technology company focused on women's intimate health. Viveve is committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System incorporates CMRF technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate neocollagenesis in a single in-office session. In the United States, the Viveve System is cleared by the Food and Drug Administration (FDA) for use in general surgical procedures for electrocoagulation and hemostasis. International regulatory approvals and clearances have been received for vaginal laxity and/or improvement in sexual function indications in more than 50 countries.
Viveve continues to advance its clinical development program in SUI. The positive topline results reported from the 3-arm feasibility study and the preclinical study outcomes are intended to support the initiation of the pivotal PURSUIT Trial and strengthen its potential to achieve its primary efficacy endpoint. As announced on July 7, 2020, Viveve received FDA approval of its Investigational Device Exemption application to conduct the multicenter, randomized, double-blinded, sham-controlled PURSUIT Trial for improvement of SUI in women.
For more information visit Viveve's website at www.viveve.com.
Safe Harbor Statement
All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the impact of the novel coronavirus termed COVID-19 on our clinical development and regulatory review and clearances and on the manufacturing, placements and patient utilization of our Viveve Systems, the performance of management and our employees, the outcome of our assessment of strategic alternatives, our ability to obtain financing, our evaluation of strategic alternatives, our ability to obtain approval or clearance for sale of our medical device for all indications sought, competition, general economic conditions and other factors that are detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware, unless required by law.
Viveve is a registered trademark of Viveve, Inc.
Investor Relations contacts:
Amato and Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com
Media contact:
Bill Berry
Berry & Company Public Relations
(212) 253-8881
bberry@berrypr.com
SOURCE: Viveve Medical, Inc.
View source version on accesswire.com:
https://www.accesswire.com/604635/Viveve-to-Present-at-HC-Wainwright-22nd-Annual-Global-Investment-Conference
FAQ
When is Viveve Medical presenting at the H.C. Wainwright conference?
Where can I watch Viveve Medical's presentation at the conference?
What is the focus of Viveve Medical's technology?
What FDA approvals has Viveve Medical received?
What is the significance of the PURSUIT Trial for Viveve Medical?
